Solid Tumor-targeting Theranostic Polymer Nanoparticle in Nuclear Medicinal Fields

Overview

Journal ScientificWorldJournal

Publisher Wiley

Specialty Biology

Date 2014 Nov 8

PMID 25379530

Citations 4

Authors

Akira Makino

Shunsaku Kimura

Affiliations

Soon will be listed here.

Abstract

Polymer nanoparticles can be prepared by self-assembling of amphiphilic polymers, and various types of molecular assemblies have been reported. In particular, in medicinal fields, utilization of these polymer nanoparticles as carriers for drug delivery system (DDS) has been actively tried, and some nanoparticulate drugs are currently under preclinical evaluations. A radionuclide is an unstable nucleus and decays with emission of radioactive rays, which can be utilized as a tracer in the diagnostic imaging systems of PET and SPECT and also in therapeutic purposes. Since polymer nanoparticles can encapsulate most of diagnostic and therapeutic agents with a proper design of amphiphilic polymers, they should be effective DDS carriers of radionuclides in the nuclear medicinal field. Indeed, nanoparticles have been recently attracting much attention as common platform carriers for diagnostic and therapeutic drugs and contribute to the development of nanotheranostics. In this paper, recent developments of solid tumor-targeting polymer nanoparticles in nuclear medicinal fields are reviewed.

Citing Articles

Novel Drug Delivery Particles Can Provide Dual Effects on Cancer "Theranostics" in Boron Neutron Capture Therapy.

Fithroni A, Inoue H, Zhou S, Hakim T, Tada T, Suzuki M Cells. 2025; 14(1.

PMID: 39791761 PMC: 11719788. DOI: 10.3390/cells14010060.

Nanomaterial Probes for Nuclear Imaging.

Phua V, Yang C, Xia B, Yan S, Liu J, Aw S Nanomaterials (Basel). 2022; 12(4).

PMID: 35214911 PMC: 8875160. DOI: 10.3390/nano12040582.

A Novel Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): "Lactosome" Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy.

Lim M, Ohtsuki T, Takenaka F, Kobayashi K, Akehi M, Uji H Life (Basel). 2021; 11(2).

PMID: 33670777 PMC: 7923095. DOI: 10.3390/life11020158.

Employment of targeted nanoparticles for imaging of cellular processes in cardiovascular disease.

Modak M, Frey M, Yi S, Liu Y, Scott E Curr Opin Biotechnol. 2020; 66:59-68.

PMID: 32682272 PMC: 7744313. DOI: 10.1016/j.copbio.2020.06.003.

Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.

Zhu L, Zhou Z, Mao H, Yang L Nanomedicine (Lond). 2016; 12(1):73-87.

PMID: 27876448 PMC: 5144490. DOI: 10.2217/nnm-2016-0316.

References

Egusquiaguirre S, Igartua M, Hernandez R, Pedraz J . Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 2012; 14(2):83-93. DOI: 10.1007/s12094-012-0766-6. View

Lee H, Hoang B, Fonge H, Reilly R, Allen C . In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res. 2010; 27(11):2343-55. DOI: 10.1007/s11095-010-0068-z. View

Wacker M . Nanotherapeutics--product development along the "nanomaterial" discussion. J Pharm Sci. 2014; 103(3):777-84. DOI: 10.1002/jps.23879. View

Cheng C, Huang C, Ho A, Peng C, Chang C, Mai F . Novel targeted nuclear imaging agent for gastric cancer diagnosis: glucose-regulated protein 78 binding peptide-guided 111In-labeled polymeric micelles. Int J Nanomedicine. 2013; 8:1385-91. PMC: 3626371. DOI: 10.2147/IJN.S42003. View

Horcajada P, Gref R, Baati T, Allan P, Maurin G, Couvreur P . Metal-organic frameworks in biomedicine. Chem Rev. 2011; 112(2):1232-68. DOI: 10.1021/cr200256v. View

Brannon-Peppas L, Blanchette J . Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004; 56(11):1649-59. DOI: 10.1016/j.addr.2004.02.014. View

Yamamoto F, Yamahara R, Makino A, Kurihara K, Tsukada H, Hara E . Radiosynthesis and initial evaluation of (18)F labeled nanocarrier composed of poly(L-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Nucl Med Biol. 2013; 40(3):387-94. DOI: 10.1016/j.nucmedbio.2012.12.008. View

Cambien B, Franken P, Lamit A, Mauxion T, Richard-Fiardo P, Guglielmi J . ⁹⁹mTcO₄--, auger-mediated thyroid stunning: dosimetric requirements and associated molecular events. PLoS One. 2014; 9(3):e92729. PMC: 3963936. DOI: 10.1371/journal.pone.0092729. View

Allmeroth M, Moderegger D, Gundel D, Koynov K, Buchholz H, Mohr K . HPMA-LMA copolymer drug carriers in oncology: an in vivo PET study to assess the tumor line-specific polymer uptake and body distribution. Biomacromolecules. 2013; 14(9):3091-101. DOI: 10.1021/bm400709z. View

10.

Hara E, Makino A, Kurihara K, Yamamoto F, Ozeki E, Kimura S . Pharmacokinetic change of nanoparticulate formulation "Lactosome" on multiple administrations. Int Immunopharmacol. 2012; 14(3):261-6. DOI: 10.1016/j.intimp.2012.07.011. View

11.

Rossin R, Pan D, Qi K, Turner J, Sun X, Wooley K . 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med. 2005; 46(7):1210-8. View

12.

Pressly E, Rossin R, Hagooly A, Fukukawa K, Messmore B, Welch M . Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined (64)Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules. 2007; 8(10):3126-34. DOI: 10.1021/bm700541e. View

13.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

14.

Hara E, Ueda M, Makino A, Hara I, Ozeki E, Kimura S . Factors influencing in vivo disposition of polymeric micelles on multiple administrations. ACS Med Chem Lett. 2014; 5(8):873-7. PMC: 4137364. DOI: 10.1021/ml500112u. View

15.

Hong Y, Zhu H, Hu J, Lin X, Wang F, Li C . Synthesis and radiolabeling of (111)In-core-cross linked polymeric micelle-octreotide for near-infrared fluoroscopy and single photon emission computed tomography imaging. Bioorg Med Chem Lett. 2014; 24(12):2781-5. DOI: 10.1016/j.bmcl.2014.03.050. View

16.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

17.

Chen Y, Li X . Near-infrared fluorescent nanocapsules with reversible response to thermal/pH modulation for optical imaging. Biomacromolecules. 2011; 12(12):4367-72. PMC: 5972015. DOI: 10.1021/bm201350d. View

18.

Hao R, Xing R, Xu Z, Hou Y, Gao S, Sun S . Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater. 2010; 22(25):2729-42. DOI: 10.1002/adma.201000260. View

19.

Hoang B, Lee H, Reilly R, Allen C . Noninvasive monitoring of the fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/CT imaging. Mol Pharm. 2009; 6(2):581-92. DOI: 10.1021/mp8002418. View

20.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View